Quantification of hepatitis B virus HBsAg: Clinical implications;Cuantificación del antígeno de superficie del virus de la hepatitis B: implicaciones clínicas

Medicina Clinica

Volumn 138, Issue 11, 2012, Pages 483-488

  Buti, Maria ^a,b   Rodríguez Frías, Francisco ^a,b   Esteban, Rafael ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Antiviral therapy; HBsAg; Hepatitis B

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON ALPHA; PEGYLATED INTERFERON ALFA; UNCLASSIFIED DRUG;

ARTICLE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN;

EID: 84859421385     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2011.04.024     Document Type: Review

References (31)

1. B.S. Blumberg, H.J. Alter, and S. Visnich A «new» antigen in leukemia sera JAMA 191 1965 541 546
2. Rotman Y, Brown AT, Hoofnagle JH. Evaluation of the patient with hepatitis B. Hepatology. 2009 (5 Suppl); 49:S22-27
3. C. Seeger, and W.S. Mason Hepatitis B virus biology Microbiol Mol Biol Rev 64 2000 51 58
4. K. Simon, V.R. Lingappa, and D. Ganem Secreted hepatitis B surface antigen polypeptides are derived from transmembrane precursor J Cell Biol 107 1988 2163 2168 (Pubitemid 19015095)
5. T. De Medina, O. Kaktor, and Y. Shaul The S promoter of HBV is regulated by positive and negative elements Mol Cell Biol 8 1988 2449 2455
6. W. Stibbe, and W.H. Gerlich Structural relationship between minor and major proteins of hepatitis B surface antigen J Virol 46 1983 626 628 (Pubitemid 13130036)
7. K.H. Heermann, U. Goldmann, W. Schwartz, T. Seyffarth, H. Baumgarten, and W.H. Gerlich Large surface proteins of HBV containing the Pre-s sequence J Virol 52 1984 396 402 (Pubitemid 15202474)
8. H.P. Dienes, W.H. Gerlich, M. Worsdorfer, G. Gerken, L. Bianchi, and G. Hess Hepatic expression patterns of the large and middle hepatitis B surface proteins in viremic and non viremic chronic hepatitis B Gastroenterology 98 1990 1017 1023 (Pubitemid 20095856)
9. D.B. Le Guillou, J.C. Duclos-Vallée, F. Eberle, F. Capel, and M.A. Petit Evaluation of an enzyme-linked immunosorbent assay for detection and quantification of hepatitis B virus PreS1 envelope antigen in serum samples: comparison with two commercial assays for monitoring hepatitis B virus DNA J Viral Hepat 7 2000 387 392
10. K. Wursthorn, J. Jaroszewicz, B.J. Zacher, M. Darnedde, R. Raupach, and I. Mederacke Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum J Clin Virol 2011 Jan 25 [Epub ahead of print]
11. J.M. Lee, and S.H. Ahn Quantification of HBsAg: Basic virology for clinical practice World J Gastroenterol 17 2011 283 289
12. J. Wiegand, H. Wedemeyer, A. Finger, B. Heidrich, J. Rosenau, and G. Michel A decline in hepatitis B virus surface antigen predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels Antivir Ther 13 2008 547 554 (Pubitemid 352016717)
13. E.K. Manesis, E.S. Hadziyannis, O.P. Angelopoulou, and S.J. Hadziyannis Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels Antivir Ther 12 2007 73 82 (Pubitemid 46340428)
14. T. Nguyen, P. Desmond, and S. Locarnini The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B Hepatol Int 3 (Suppl 1) 2009 S5 15
15. K. Wursthorn, M. Lutgehetmann, M. Dandri, T. Volz, P. Buggisch, and B. Zollner Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B Hepatology 44 2006 675 684 (Pubitemid 44433724)
16. B. Werle-Lapostolle, S. Bowden, S. Locarnini, K. Wursthorn, J. Petersen, and G. Lau Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 2004 1750 1758 (Pubitemid 38736340)
17. R.P. Perrillo Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns Hepatology 49 2009 1063 1065
18. A. Thompson, T. Nguyen, D. Iser, A. Ayres, K. Jackson, and M. Littlejohn Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers Hepatology 51 2010 1933 1944
19. G.C. Kimbi, A. Kramvis, and M.C. Kew Integration of hepatitis B virus DNA into chromosomal DNA during acute hepatitis B World J Gastroenterol 11 2005 6416 6421 (Pubitemid 43136875)
20. C.A. Bill, and J. Summers Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration Proc Natl Acad Sci USA 101 2004 11135 11140 (Pubitemid 38989596)
21. T. Nguyen, A.J.V. Thompson, S. Bowden, C. Croagh, S. Bell, and P.V. Desmond Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia J Hepatol 52 2010 508 513
22. J. Jaroszewicz, B.C. Serrano, K. Wursthorn, K. Deterding, J. Schlue, and R. Raupach Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective J Hepatol 52 2010 514 522
23. M. Brunetto, F. Oliveri, P. Colombato, F. Moriconi, P. Ciccorossi, and B. Coco Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers Gastroenterology 139 2010 483 490
24. M.R. Brunetto, F. Moriconi, F. Bonino, G.K. Lau, P. Farci, and C. Yurdayin Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology 49 2009 1141 1150
25. R. Moucari, V. Mackiewicz, O. Lada, M.P. Ripault, C. Castelnau, and M. Mratinot-Peignoux Early serum HBsAg drop:a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients Hepatology 49 2009 1151 1157
26. J. Chen, Z. Wang, Y. Guo, J. Peng, J. Sun, and C.S. Ahmed Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peginterferon-alpha-2a Antiviral Res 81 2009 88 91
27. V. Rijckborst, B. Hansen, Y. Cakaloglu, P. Ferenci, F. Tabak, and M. Akdogan Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels Hepatology 52 2010 454 461
28. M. Sonneveld, V. Rijckborst, C. Boucher, B. Hansen, and H. Janssen Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline Hepatology 52 2010 1251 1257
29. E.J. Gane, E.J. Heathcote, P. Marcellin, G. Dusheiko, I. Jacobson, and R. de Man HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment [Abstract] J Hepatol 52 Suppl 1 2010 S388
30. Y.F. Liaw, E. Gane, N. Leung, S. Zeuzem, Y. Wang, C.L. Lai the GLOBE Study Group 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 2009 486 495
31. K. Wursthorn, M. Jung, A. Riva, Z. Goodman, P. Lopez, and W. Bao Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients Hepatology 52 2010 1611 1620